BMJ Case Reports 2017; doi:10.1136/bcr-2017-220744
  • Unexpected outcome (positive or negative) including adverse drug reactions

Radiation retinopathy treated successfully with aflibercept

  1. Ayad Al-bermani2
  1. 1Ophthalmology Department, Cardiff University, Cardiff, UK
  2. 2Ophthalmology Department, University Hospital Wales, Cardiff, UK
  1. Correspondence to Pakinee Pooprasert, pooprasertp{at}
  • Accepted 25 October 2017
  • Published 9 November 2017


Aflibercept (aflibercept) is a novel anti-vascular endothelial growth factor drug indicated for wet age-related macular degeneration and macular oedema secondary to retinal vein occlusion and diabetic macular oedema. While only newly introduced on the market, it is growing in popularity and over 5.5 million doses have been prescribed worldwide. Due to its versatile mechanism, it is indicated for numerous eye pathologies, and in particular, has been adapted to treat various types of retinopathy. To our knowledge, this is the first case report of solely using aflibercept to treat cystoid macular oedema in radiation retinopathy.


  • Contributors TY-Z and AA-b were responsible for collecting patient information and results while PP was responsible for writing the case report.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article